Diabetic nephropathy

Diabetes Care

Volumn 25, Issue SUPPL. 1, 2002, Pages

  Molitch, Mark E ^a   DeFronzo, Ralph A ^a   Franz, Marion J ^a   Keane, William F ^a   Mogensen, Carl Erik ^a   Parving, Hans Henrik ^a   Steffes, Michael W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIALYSIS; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; REVIEW; RISK FACTOR;

EID: 23944511753     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.2007.s85     Document Type: Review

References (15)

1. American Diabetes Association. Diabetes 2001 Vital Statistics. Alexandria, VA, ADA, 2001
2. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 25: (Suppl. 1):S33-S49, 2002
3. American Diabetes Association: Treatment of hypertension in adults with diabetes (Position Statement). Diabetes Care 25 (Suppl. 1):S71-S73, 2002
4. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kid Dis 36: 646-661, 2000
5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
6. DeFronzo RA: Diabetic nephropathy: etiologic and therapeutic considerations. Diabetes Rev 3:510-564, 1995
7. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
8. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde BS, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 345:851-860, 2001
9. Lewis EJ, Hunsicker LG, Bain RP, and Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
10. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving H-H, Passa P, Steffes MW, Striker GE, Viberti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080-1084, 1995
11. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomised controlled trial of dual blockade ofrenin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 1440-1444, 2000
12. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
13. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing the risk of macrovascular complications in type 2 diabetes (UKPDS 39). BMJ 317:713-720, 1998
14. UK Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
15. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 317: 703-713, 1998